Highlights
- Prescient Therapeutics’ abstract for PTX-100 has been published on the American Society of Hematology (ASH) website
- PTX-100 Phase 1b study is ongoing with patients with refractory and relapsed TCL
- The trial results are anticipated to be released on the ASX in December 2023
Prescient Therapeutics Limited (ASX: PTX) informed that its PTX-100’s abstract has been published on the American Society of Hematology (AXH) website before the scheduled presentation on 9 December 2023.
The abstract concerns the interim results from the ongoing Phase 1b study examining PTX-100 in patients with relapsed and refractory T-cell lymphoma (TCL).
Data source: Company update
The abstract highlights that as at the cut-off date, total 14 patients were treated, of which 10 patients underwent response assessment after four-cycle therapy and the overall response rate was 40%. For the abstract, data cut off was 10 July 2023 and the study is going on.
Data source: Company update
The results of the PTX-100 Phase 1b trial that comprises additional and updated data are likely to be announced in December 2023, after the ASH presentation.
PTX shares traded at AU$0.056 apiece at the time of writing on 6 November 2023.